RLMD Stock — Relmada Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$4.54

Market cap

$475.75M

Price action

19 metrics

Price change (1W)

-0.2%

Price change (30D)

-17.0%

Price change (3M)

-28.3%

Price change (6M)

-4.8%

Price change (YTD)

-6.0%

Price change (1Y)

+219.7%

Trailing year

Price change (5Y)

-81.6%

52-week high

$7.86

52-week low

$1.37

Change from 52-week high

-42.2%

Change from 52-week low

+231.4%

Annualized volatility

105.2%

Beta

1.7

RSI (14D)

38.4

Price vs SMA 50

-15.7%

Price vs SMA 200

-17.1%

Avg volume (3M)

1.71M

Relative volume

0.8

Average dollar volume

$10.06M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

106.67M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

150,267.7×

reciprocal yield 0.0%

P / book

2.3

reciprocal yield 43.4%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-13.0%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-08-06

Profitability

9 metrics

Gross margin

14.9%

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

$473

Operating profit (TTM)

−$65.13M

Net income (TTM)

−$61.93M

Trailing 12 months

Diluted EPS (TTM)

$-0.90

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$0.78

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

$3,166

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+238.6%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-30.0%

Return on assets

-28.3%

Debt / equity

—

Current ratio

29.5

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

29.5

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$217.73M

Latest balance sheet

Cash & equivalents

$11.33M

Total assets

$219.06M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$45.99M

Capital expenditures (TTM)

—

R&D (TTM)

$28.59M

SG&A (TTM)

—

Stock compensation (TTM)

$8.74M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

127

13F filer change QoQ

+23

Institutional ownership

94.2%

Short interest

3 metrics

Short interest

12.1%

Latest settlement · 9.4 days to cover

Days to cover

9.4d

Short-squeeze score

61 / 100

Insider activity

2 metrics

Net insider buying (90D)

—

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

RLMD · Relmada Therapeutics, Inc.

RLMD metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search